ClinicalTrials.gg
CompletedNCT05857124Updated Jun 15, 2025

A Study Evaluating the Efficacy of the Vielight Neuro RX Gamma in the Treatment of Post COVID-19 Cognitive Impairment

A Phase 1 interventional study of Vielight Neuro RX Gamma active device and Vielight Neuro RX Gamma sham device in Post COVID-19 Cognitive Impairment, sponsored by Vielight Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-06-15.

Sponsored by Vielight Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Sep 2024, 2 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,860 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Enrollment
912th of 1,322
36 · median 92
Started
2023
with 130 others
Phase 1
178 of 1,860
10 open now
Registered
1,637th of 1,860
by date

Among the 1,860 studies in COVID-19 with a site in United States, this one is the 912th largest by enrollment of the 1,322 interventional ones that give a count, is one of 131 that started in 2023, is one of 178 in phase 1, and was the 1,637th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,860 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,860 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

Some people who have been infected with the virus that causes COVID-19 can experience long-term effects from their infection, known as post COVID-19 conditions (PCC) or long COVID1. The medical circles often describe it as post-acute sequelae of Covid-19 (PASC). People with post-COVID conditions can have a wide range of symptoms that can last more than four weeks or even months after infection. Sometimes the symptoms can even go away or come back again. The Centers for Disease and Prevention (CDC) listed a constellation of 19 symptoms related to post COVID-19.

In research, brain fog is prominent among the most reported neurological symptoms which also include, numbness, tingling, headache, dizziness, blurred vision, tinnitus, and fatigue that last more than a year post-infection.

Vielight Inc. has developed a compact and portable device named the "Vielight RX Gamma", which is suitable for home use. The intervention is based on the science of photobiomodulation (PBM) which utilizes certain light energy to modify cellular functions. The fundamental mechanisms of PBM are based on the absorption of photons by the mitochondria to modulate cellular functions. The Vielight Neuro RX Gamma delivers light of specific wavelengths (810 nm), power and duration to the brain/nasal cavity to achieve this. The biological process involves numerous interacting mechanisms that modulate bodily functions. One result of PBM is the benefits it could offer the post COVID-19 (long COVID) population. The Vielight Neuro RX Gamma emitting NIR might reduce inflammatory markers relevant to COVID-19 and since it pulses at 40 Hz can activate the non-inflammatory M2-genotype microglia to remove markers of Alzheimer disease, such as beta-amyloid and possibly tau deposits. Using Vielight Neuro RX Gamma, the same activation of non-inflammatory markers might occur with post COVID-19 (long-COVID) patient population as well as the reduction in the brain fog.

This trial utilizes a completely remote and virtual design. It is a double blind randomized controlled trial that is expected to involve 36 participants who are confirmed to have Post- COVID cognitive impairment. Eighteen of the participants will be randomized to the active Vielight RX Gamma protocol, and the other eighteen participants will be randomized to the sham Vielight RX Gamma regimen. The trial will study patients over 120 days and ask them to track their symptoms in a daily survey.

03

Conditions studied

  • Post COVID-19 Cognitive Impairment
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female age 18-65.
  • Diagnosed with Post COVID cognitive impairment who meets WHO-defined post-COVID-19 condition
  • (MMSE) score of \<27
  • Capable of filling out an online patient diary in English.

Exclusion criteria

Exclusion Criteria:

  • Current symptoms are explained by a psychiatric or neurological disorder
  • Having or history of any major neurological or psychiatric illness
  • Pregnant
  • Physical, cognitive, or language impairments sufficient to adversely affect data derived from cognitive assessments or History of mild traumatic brain injury (TBI)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Active treatment devices

    Vielight Neuro RX Gamma active device

    Device: Vielight Neuro RX Gamma active device

  • Sham comparator
    Sham devices

    Vielight Neuro RX Gamma sham device

    Device: Vielight Neuro RX Gamma sham device

Interventions

  • DeviceVielight Neuro RX Gamma active device

    The Vielight Neuro RX Gamma active device is a home-use photobiomodulation (PBM) device designed to deliver near-infrared (810 nm) light (or photons) to the brain/scalp and nasal tissues.

  • DeviceVielight Neuro RX Gamma sham device

    The Vielight Neuro RX Gamma sham device is a home-use device similar to the Vielight Neuro RX Gamma active device, but acting as a sham.

06

What researchers measure

Primary outcomes

  1. The change in the combined results of 7 Creyos items: Spatial Planning, Monkey Ladder, Rotations, Feature Match, Paired Associates, Token Search, Polygons.

    Time frame: from baseline to Day 56

Secondary outcomes

  1. Creyos scores of the 5 remaining tests (i.e. Grammatical Reasoning, Spatial Span, Digit Span, Odd One Out, Double Trouble)

    Time frame: 0, 14, 28, 56 and 84 days

  2. EQ-5D-5L Quality of Life

    Time frame: 0, 14, 28, 56 and 84 Days

  3. Fatigue Assessment Scale (FAS)

    Time frame: 0, 56 and 84 Days

  4. The perceived deficits questionnaire - 20 item version (PDQ-20)

    Time frame: 0, 56 and 84 days

  5. Compliance and Technical Complications

    Time frame: 0 to Day 56

  6. Modified Symptom Burden Questionnaire

    (Breathing Pain Fatigue Memory, Thinking and Communication Sleep Ears, Nose and Throat Stomach and Digestion Other Symptoms)

    Time frame: 0 and 56 Days

Other outcomes

  1. Exploratory Endpoints

    Statistical analysis of the Creyos changes between treatment groups may warrant further exploration of the primary endpoint model

    Time frame: 0 to Day 56

07

Study locations

1 site
  • Ascada Research
    Fullerton, California 92835, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Sep 2024, 17 months.

Of 233 industry-sponsored phase 1 interventional studies under COVID-19, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 12. This study's 17 months is above that.

Counting every sponsor, half of 384 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2023
First posted
May 12, 2023
StartActual
Apr 1, 2023
Primary completionActual
Sep 1, 2024
CompletionActual
Jan 16, 2025
Last update
Jun 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05857124
Lead sponsor
Vielight Inc.
Responsible party
Sponsor
First posted
May 12, 2023
Start date
Apr 1, 2023
Primary completion
Sep 1, 2024
Completion
Jan 16, 2025
Last update
Jun 15, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion